Market Research Logo

Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2018

Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2018 provides an overview of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Overview
3 Products under Development
3.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
3.2 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
3.3 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
3.4 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
3.5 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
4 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies
4.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development
4.2 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
5 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview
5.1 AnGes Inc Company Overview
5.2 AngioCure, Inc. Company Overview
5.3 Becton Dickinson and Co Company Overview
5.4 Boston Scientific Corp Company Overview
5.5 C. R. Bard Inc Company Overview
5.6 Contego Medical, LLC Company Overview
5.7 eucatech AG Company Overview
5.8 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
5.9 M.A. Med Alliance SA Company Overview
5.10 Medtronic plc Company Overview
5.11 Micell Technologies Inc Company Overview
5.12 Pulsus Medical LLC (Inactive) Company Overview
5.13 QT Vascular Ltd Company Overview
5.14 QualiMed Innovative Medizinprodukte GmbH Company Overview
5.15 SiL Vascular Ltd Company Overview
5.16 Spectranetics Corp Company Overview
5.17 SurModics Inc Company Overview
5.18 TransMed7 LLC Company Overview
5.19 Vascular Nanotransfer Technologies Company Overview
6 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Recent Developments
6.1 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
6.2 May 16, 2018: Surmodics Announces Leadership Change and Appointment of Interim CFO
6.3 May 11, 2018: Terumo Appoints its U.S.-based Subsidiary's Associate as the Fifth Terumo Fellow
6.4 May 11, 2018: Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board
6.5 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy
6.6 May 02, 2018: Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance
6.7 May 02, 2018: CORRECTING and REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance
6.8 May 02, 2018: Cardiovascular Systems Reports Fiscal 2018 Third-Quarter Financial Results
6.9 Apr 26, 2018: Charing Cross Symposium 2018: Real World DCB Registry BIOLUX P-III Shows Excellent 12-Month Results in the Full Cohort and BTK Subgroup
6.10 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018
6.11 Apr 25, 2018: Xianjian Technology Receives the Most Attention from Institutional Investors
6.12 Apr 23, 2018: Medtronic IN.PACT Admiral Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions
6.13 Apr 20, 2018: Cook Medical Appoints Christina Anne Vice President of Distribution Channel Management
6.14 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics
6.15 Mar 23, 2018: 2017 fiscal year: B. Braun increases sales and earnings, with investments of one billion euros
6.16 Feb 28, 2018: Daiichi Sankyo Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline
6.17 Feb 23, 2018: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018
6.18 Feb 21, 2018: Daiichi Sankyo Selected for 2018 Certified Health and Productivity Management Organization (White 500)
6.19 Feb 13, 2018: Four start-ups chosen for the B. Braun Accelerator Program
6.20 Feb 08, 2018: Terumo Revises the Full-Year Results Forecast for FY 2017
6.21 Feb 08, 2018: Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance
6.22 Feb 07, 2018: Cardiovascular Systems Reports Fiscal 2018 Second-Quarter Financial Results
6.23 Feb 02, 2018: Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018
6.24 Feb 02, 2018: Cardiovascular Systems Appoints Jeff Points as Chief Financial Officer
6.25 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017
6.26 Jan 30, 2018: United Health Products Issues Update on HemoStyp South Korea MFDS Application
6.27 Jan 30, 2018: IN.PACT Admiral Demonstrates Consistent and Durable Outcomes in New Two-Year Japan Data and IN.PACT Global Critical Limb Ischemia Cohort Analysis
6.28 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
6.29 Jan 25, 2018: Terumo Announces Change of Directors and Executive Officers
6.30 Jan 24, 2018: Cardiovascular Systems Appoints Rhonda Robb as New Chief Operating Officer
6.31 Jan 18, 2018: BD Announces Completion of Enrollment in the Lutonix 014 Drug Coated Balloon Below-The-Knee Trial
6.32 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017
6.33 Jan 07, 2018: LifeTech Scientific and Ally Bridge Group Form China-Global Medtech Investment and Operating Partnership
6.34 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region
6.35 Dec 13, 2017: Terumo Constructs a New Building in Yamaguchi, Japan To Strengthen Production Operations in Interventional Systems
6.36 Dec 12, 2017: B. Braun establishes a subsidiary in Zambia
6.37 Nov 30, 2017: Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary
6.38 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results
6.39 Nov 15, 2017: Heiko Schipper is the new CEO and Head of the Consumer Health Division at Bayer
6.40 Nov 13, 2017: Philips showcases integrated vascular solutions at VEITH 2017
6.41 Nov 08, 2017: Surmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance
6.42 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue
6.43 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report
6.44 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017
6.45 Oct 25, 2017: Cardiovascular Systems Reports Fiscal 2018 First-Quarter Financial Results
6.46 Oct 25, 2017: Bard Announces Third Quarter Results
6.47 Oct 23, 2017: Surmodics Announces First Patient Enrolled in TRANSCEND Pivotal Clinical Trial for SurVeil Drug-Coated Balloon
6.48 Oct 17, 2017: Bayer Appoints Brenda L. Raphael Senior Vice President and General Manager of Therapeutics Business Unit for Consumer Health
6.49 Oct 10, 2017: Terumo Provides Update on Impact from Hurricane Maria
6.50 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria
6.51 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary
6.52 Sep 26, 2017: MicroVention Celebrates Grand Opening of New Worldwide Innovation Center in Aliso Viejo, California
6.53 Sep 25, 2017: The T.I.N.T.I.N. trial evaluating the combined therapy of Luminor DCB and iVolution SX stent
6.54 Sep 21, 2017: Luminor 14m has received the Canadian Medical Device License
6.55 Sep 18, 2017: CIRSE 2017: BIOTRONIK Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
6.56 Sep 18, 2017: Eurocor announces the presentation of the 12 months data of the Freeway Stent Study at CIRSE in Copenhagen on Sept. 18, 2017
6.57 Sep 18, 2017: Cardiovascular Systems Announces Anticipated Revenue Impact from Hurricanes Harvey and Irma
6.58 Sep 15, 2017: Daiichi Sankyo Listed on the Dow Jones Sustainability Indices World Index
6.59 Sep 14, 2017: Efficacy of Philips' Stellarex .035 low-dose drug-coated balloon demonstrated in clinical trial at two years
6.60 Sep 13, 2017: Six-Month Data from the Surmodics SurVeil Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2017
6.61 Sep 13, 2017: New Unpublished Clinical Trial Results of Stellarex DCB Announced At VIVA 17
6.62 Sep 12, 2017: Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials
6.63 Sep 08, 2017: Medtronic Announces Japanese Regulatory Approval for the IN.PACT Admiral Drug-Coated Balloon
6.64 Sep 07, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of October 1, 2017
6.65 Aug 28, 2017: C. R. Bard Receives FDA Premarket Approval of the LUTONIX 035 Drug Coated Balloon as the First and Only DCB for the Treatment of Patients with Dysfunctional AV Fistulae
6.66 Aug 22, 2017: Medtronic Reports First Quarter Financial Results
6.67 Aug 03, 2017: Surmodics Reports Third Quarter Fiscal 2017 Results and Updates Fiscal 2017 Guidance
6.68 Aug 03, 2017: Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million
6.69 Aug 02, 2017: Cardiovascular Systems Reports Fiscal 2017 Fourth-Quarter Financial Results
6.70 Jul 31, 2017: QT Vascular begins enrollment in US pivotal study of its drug-coated peripheral balloon
6.71 Jul 31, 2017: Dr. Joachim Schulz joins the Management Board of B. Braun Melsungen
6.72 Jul 28, 2017: Indonesian Minister of Health Launches New German Pharmaceutical Factory in Karawang
6.73 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017
6.74 Jul 26, 2017: Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
6.75 Jul 26, 2017: Surmodics Receives IDE Approval to Initiate Pivotal Trial of the SurVeil Drug-Coated Balloon
6.76 Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell
6.77 Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced
6.78 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
6.79 Jun 14, 2017: Spectranetics Announces Election of New Chairperson of the Board of Directors
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Table 2: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
Table 3: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
Table 4: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
Table 5: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials
Table 6: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development
Table 7: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Table 8: AnGes Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status
Table 10: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description
Table 11: AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 12: AngioCure TOP-C Smart Balloon Catheter - Product Status
Table 13: AngioCure TOP-C Smart Balloon Catheter - Product Description
Table 14: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Lutonix Drug Coated Balloon Catheter - Long Lesion - Product Status
Table 16: Lutonix Drug Coated Balloon Catheter - Long Lesion - Product Description
Table 17: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Ranger Drug-Coated Balloon - Product Status
Table 19: Ranger Drug-Coated Balloon - Product Description
Table 20: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 21: Ranger Drug-Coated Balloon - A Randomized Trial Comparing Drug-coated Balloon and Regular Balloon for Dialysis Access Stent Graft Restenosis
Table 22: Ranger Drug-Coated Balloon - Clinical Study of the Boston Scientific Paclitaxel-coated PTA (Percutaneous Transluminal Angioplasty) Balloon Catheter (Ranger and Ranger SL (OTW) DCB) in China
Table 23: Ranger Drug-Coated Balloon - JETStream AtheRectomy with Adjunctive Paclitaxel-coated Balloon Angioplasty Versus Balloon Angioplasty Followed by Paclitaxel-coated Balloon in Treating Complex Denovo Femoropopliteal Arterial Disease: JET-RANGER
Table 24: Ranger Drug-Coated Balloon - Prospective, Randomized, Multi-center Study for the Treatment of Subjects with Symptomatic Femoropopliteal Artery Disease with the Ranger Paclitaxel Coated PTA Balloon Catheter (Study Arm) Versus the IN.PACT Drug Eluting Balloon (Control Arm)
Table 25: Ranger Drug-Coated Balloon - Prospective, Randomized, Multicenter Clinical Study of the Hemoteq Ranger Paclitaxel-coated PTA Balloon Catheter (Ranger DCB) in Comparison to Uncoated PTA Balloons in Femoropopliteal Lesions
Table 26: Ranger Drug-Coated Balloon - RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER Paclitaxel Coated Balloon Versus Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Table 27: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Lutonix - ISR - Product Status
Table 29: Lutonix - ISR - Product Description
Table 30: Lutonix 014 DCB Catheter - Product Status
Table 31: Lutonix 014 DCB Catheter - Product Description
Table 32: C. R. Bard Inc - Ongoing Clinical Trials Overview
Table 33: Lutonix 014 DCB Catheter - A Prospective, Multicenter, Registry of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries (LEVANT 2 Safety Registry)
Table 34: Lutonix 014 DCB Catheter - A Prospective, Multicenter, Single Arm Real-world Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon Percutaneous Transluminal Angioplasty (PTA) Catheter for Treatment of Below-the-Knee (BTK) Arteries
Table 35: Lutonix 014 DCB Catheter - A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-knee (BTK) Arteries: Lutonix BTK Trial
Table 36: Lutonix 014 DCB Catheter - Drug Eluting Balloon in Peripheral Intervention for Below-the-knee Arteries with Freeway and Lutonix
Table 37: Lutonix 014 DCB Catheter - Evaluation of Paclitaxel in Patients with CLI (Critical Limb Ischemia) and Femoropopliteal Occlusive Disease Treated with DCB Angioplasty
Table 38: Lutonix 014 DCB Catheter - Tack Optimized Balloon Angioplasty Study for Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System
Table 39: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 40: Tibial Artery Drug Eluting Balloon - Product Status
Table 41: Tibial Artery Drug Eluting Balloon - Product Description
Table 42: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
Table 43: Support - Product Status
Table 44: Support - Product Description
Table 45: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 46: FemFlow Drug-Eluting Peripheral Balloon Catheter (DEB) - Product Status
Table 47: FemFlow Drug-Eluting Peripheral Balloon Catheter (DEB) - Product Description
Table 48: M.A. Med Alliance SA Pipeline Products & Ongoing Clinical Trials Overview
Table 49: SELUTION Sirolimus Coated Balloon - Product Status
Table 50: SELUTION Sirolimus Coated Balloon - Product Description
Table 51: M.A. Med Alliance SA - Ongoing Clinical Trials Overview
Table 52: SELUTION Sirolimus Coated Balloon - SELUTION Sirolimus Coated PTA Balloon Catheter Prospective, Controlled, Multi-center, Open, Single-arm Clinical Investigation for the Treatment of Patients with Femoropopliteal Artery Lesions with a Novel Drug Coated Balloon
Table 53: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
Table 54: IN.PACT Admiral DEB - BTK - Product Status
Table 55: IN.PACT Admiral DEB - BTK - Product Description
Table 56: IN.PACT AV Access Drug-Coated Balloon - 4 - 7mm - Product Status
Table 57: IN.PACT AV Access Drug-Coated Balloon - 4 - 7mm - Product Description
Table 58: IN.PACT AV Access Drug-Coated Balloon - 8 -12mm - Product Status
Table 59: IN.PACT AV Access Drug-Coated Balloon - 8 -12mm - Product Description
Table 60: Medtronic plc - Ongoing Clinical Trials Overview
Table 61: IN.PACT AV Access Drug-Coated Balloon - 4 - 7mm - A Randomized Controlled Trial of Drug-Eluting Balloon Angioplasty in Venous Anastomotic Stenosis of Dialysis Arteriovenous Graft
Table 62: IN.PACT AV Access Drug-Coated Balloon - 4 - 7mm - Study of IN.PACT Admiral Drug-coated Balloon for a New Indication in Subjects with End-stage Renal Disease
Table 63: IN.PACT Admiral DEB - BTK - Randomized Study of IN.PACT 014 Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Chronic Total Occlusions in the Infrapopliteal Arteries
Table 64: IN.PACT AV Access Drug-Coated Balloon - 8 -12mm - A Randomized Controlled Trial of Drug-Eluting Balloon Angioplasty in Venous Anastomotic Stenosis of Dialysis Arteriovenous Graft
Table 65: Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 66: Drug-Coated Balloon - Product Status
Table 67: Drug-Coated Balloon - Product Description
Table 68: Pulsus Medical LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 69: Micro-Perforated Catheter Balloon Drug Delivery System - Product Status
Table 70: Micro-Perforated Catheter Balloon Drug Delivery System - Product Description
Table 71: QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 72: Chocolate Touch - Product Status
Table 73: Chocolate Touch - Product Description
Table 74: QT Vascular Ltd - Ongoing Clinical Trials Overview
Table 75: Chocolate Touch - A Randomized Trial to Confirm the Safety and Effectiveness of Chocolate Touch Paclitaxel Coated Balloon Catheter, in Above the Knee Lesions
Table 76: QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 77: Kinesyx-Based Peripheral Drug Coated Balloon - Product Status
Table 78: Kinesyx-Based Peripheral Drug Coated Balloon - Product Description
Table 79: SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 80: Peripheral Vascular Balloon - Product Status
Table 81: Peripheral Vascular Balloon - Product Description
Table 82: Spectranetics Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 83: Stellarex 0.014” Drug-Coated Balloon - Below The Knee (BTK) - Product Status
Table 84: Stellarex 0.014” Drug-Coated Balloon - Below The Knee (BTK) - Product Description
Table 85: Stellarex Drug Coated Balloon - Above-The-Knee - Product Status
Table 86: Stellarex Drug Coated Balloon - Above-The-Knee - Product Description
Table 87: Spectranetics Corp - Ongoing Clinical Trials Overview
Table 88: Stellarex Drug Coated Balloon - Above-The-Knee - Economic Evaluation Comparing Standard Balloon Angioplasty Versus Drug-eluted Balloon or Laser-excimer in Association with Drug-eluted Balloon in the Treatment of Femoropopliteal Artery In-stent Restenosis
Table 89: Stellarex Drug Coated Balloon - Above-The-Knee - Prospective, Randomized, Single-blind, U.S. Multi-center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon: ILLUMENATE Pivotal
Table 90: Stellarex Drug Coated Balloon - Above-The-Knee - Prospective, Single-arm, Global Multi-center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery (SFA) and/or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty (PTA) Balloon and in In-Stent Restenosis: ILLUMENATE GLOBAL and ISR
Table 91: Stellarex Drug Coated Balloon - Above-The-Knee - Stellarex Vascular E-Registry
Table 92: SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 93: Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Status
Table 94: Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Description
Table 95: Drug Coated Balloon - Below The Knee (BTK) - Product Status
Table 96: Drug Coated Balloon - Below The Knee (BTK) - Product Description
Table 97: SurVeil Drug Coated Balloon - Peripheral Artery Disease - Product Status
Table 98: SurVeil Drug Coated Balloon - Peripheral Artery Disease - Product Description
Table 99: SurModics Inc - Ongoing Clinical Trials Overview
Table 100: SurVeil Drug Coated Balloon - Peripheral Artery Disease - A Prospective, Multi-center, Single-arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects with De Novo Lesions of the Femoropopliteal Artery
Table 101: SurVeil Drug Coated Balloon - Peripheral Artery Disease - The Randomized and Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-coated Balloon in the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-coated Balloon
Table 102: TransMed7 LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 103: Zeppelin II - Product Status
Table 104: Zeppelin II - Product Description
Table 105: Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview
Table 106: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Status
Table 107: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Description
Table 108: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Status
Table 109: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Description
Table 110: Glossary
1.2 List of Figures
Figure 1: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development
Figure 2: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory
Figure 3: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path
Figure 4: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date
Figure 5: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report